The CMAHOGANY trial combined retifanlimab (PD-1 inhibitor) with margetuximab for the first-line treatment of HER2-positive GC, and the results exhibited an ORR of 53% and a DCR of 73% (44). The gene discussed is ERBB2; the disease is gastric cancer.